Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

Germani MM. et al, (2025), Journal of Clinical Oncology, 43, 3184 - 3197

Clinical Significance of Extrachromosomal DNA in FGFR2 -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience

Aoki Y. et al, (2025), JCO Precision Oncology

HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer.

Loeffler CML. et al, (2025), Nature communications, 16

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR‐SCREEN‐2 Study

Hashimoto T. et al, (2025), Cancer Science, 116, 2218 - 2231

Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors.

Jubashi A. et al, (2025), JCO precision oncology, 9

Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.

Kato T. et al, (2025), British journal of cancer, 133, 111 - 120

Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.

Okazawa-Sakai M. et al, (2025), Journal of gynecologic oncology, 36

Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Sawada K. et al, (2025), Cancer research communications, 5, 857 - 870

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study

Fujisawa T. et al, (2025), JCO Precision Oncology

Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer

Inoue K. et al, (2025), JCO Precision Oncology

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing

Kobayashi S. et al, (2025), International Journal of Clinical Oncology, 30, 605 - 654

Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

Takei S. et al, (2025), Annals of Surgery

Data from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025), Cancer Immunology Research, 13, 353 - 364

Supplementary Figure S1 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S2 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S3 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S4 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S5 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S6 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Load More

1
2
3
4
5
6
7
...
»